BioMed Research International

Research Article

The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease

Table 1

Baseline characteristics of different parameter degrees in CLD patients. HC: healthy control; CHB: chronic hepatitis B; NAFLD: nonalcoholic fatty liver disease; HCC: hepatocellular carcinoma; PBC: primary biliary cholangitis; AIH: autoimmune hepatitis; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alb: albumin; GGT: gamma-glutamyl transferase; CHOL: cholesterol; TG: triglyceride; FPG: fasting plasma glucose; UA: uric acid; TB: total bilirubin; DB: direct bilirubin; AFP: alpha fetoprotein; WBC: white blood cells; N: neutrophils; L: lymphocytes; PLT: platelet; G: stages of hepatitis activity; S: liver fibrosis stage.


	HC	CHB	NAFLD	HCC	PBC	AIH

	12	24	18	13	16	27
Gender ( (%))
Male	5 (41.6%)	16 (66.7%)	11 (61.1%)	9 (69.2%)	0 (00.0%)	3 (11.1%)
Female	7 (58.4%)	8 (33.3%)	7 (38.9%)	4 (31.8%)	16 (100.0%)	24 (88.9%)
Age ( (IQR))	44.5 (33.25, 50.5)	28 (25, 34)	32 (24, 54)	60 (47.5, 65.5)	53 (46, 56.5)	50.5 (45.25, 57.5)
BMI (kg/m²,)
ALT (IU/L, (IQR))	19 (16, 20.5)	210 (115, 317.5)	148 (88, 206)	27 (21.5, 38.5)	78 (34.5, 118.5)	103 (50.25, 271.5)
AST (IU/L, (IQR))	18 (15, 21.75)	98 (76.5, 133)	74 (46, 79)	35 (20.5, 53.5)	60 (38, 88)	110 (44.75, 298.25)
GGT (IU/L, (IQR))	13.5 (10.75, 20.75)	71 (29, 229.5)	74 (50, 155)	53 (16.5, 265)	128 (59.5, 528)	283.5 (83, 439.25)
CHOL (mmol/L, )
TG (mmol/L, )
FPG (mmol/L, )
UA (μmol/L, )
TB (mg/dL, )
DB (mg/dL, (IQR))	3.05 (2.18, 3.25)	6.4 (5.35,9.15)	4 (2.7, 5.4)	2.8 (1.9, 3.65)	1.9 (1.35, 7.4)	8.9 (2.8, 19.55)
AFP (ng/mL, (IQR))	3.38 (1.43, 4.82)	8.11 (3.08, 11.04)	2.34 (1.89, 4.75)	79.33 (5.71, 253.3)	1.86 (1.71, 3.125)	3.85 (2.13, 6.44)
WBC ()
N ()
L ( (IQR))	1.75 (0.98, 2.38)	2.1 (2, 2.35)	2.5 (1.7, 2.8)	1.2 (0.6, 2.2)	1.6 (1.45, 2.25)	1.35 (1, 1.88)
PLT ()
Stages of hepatitis activity
	12	0	1	2	1	0
	0	9	15	9	7	4
	0	7	2	2	8	17
	0	8	0	0	0	6
Liver fibrosis stage
	12	12	9	2	4	2
	0	9	6	3	5	11
	0	2	2	5	4	9
	0	1	1	4	3	5